JAMA dermatology · 2014
Retreatment with omalizumab results in rapid remission in chronic spontaneous and inducible urticaria.
Сравнительное исследованиеСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Metz Martin, Ohanyan Tatevik, Church Martin K, Maurer Marcus
Аннотация
IMPORTANCE: Omalizumab has emerged as a novel and effective treatment option for patients with antihistamine-resistant chronic urticaria. It is unclear whether patients with recurrent urticaria symptoms after discontinuation of omalizumab treatment can benefit from retreatment.
OBJECTIVE: To assess the response of patients with chronic urticaria who receive omalizumab retreatment.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective analyses were conducted of outpatients treated at an urticaria specialist center of a university hospital. Participants included 25 consecutive patients (aged 18-74 years; 18 women) with chronic spontaneous urticaria, chronic inducible urticaria, or both who showed complete response to omalizumab treatment, experienced relapse after discontinuation of treatment, and received retreatment with omalizumab.
INTERVENTIONS: Subcutaneous treatment with omalizumab (150-600 mg/mo).
MAIN OUTCOMES AND MEASURES: Response after retreatment was assessed by the urticaria activity score in patients with chronic spontaneous urticaria and by trigger threshold testing (in patients with cold urticaria or symptomatic dermographism) and/or a carefully determined history (in patients with cholinergic urticaria, solar urticaria, or pressure urticaria). Adverse events were documented.
RESULTS: All patients experienced complete response after retreatment. None of the patients reported relevant adverse events during omalizumab treatment and retreatment.
CONCLUSIONS AND RELEVANCE: Omalizumab retreatment is effective and safe in patients with chronic urticaria who have benefited from initial omalizumab treatment.
OBJECTIVE: To assess the response of patients with chronic urticaria who receive omalizumab retreatment.
DESIGN, SETTING, AND PARTICIPANTS: Retrospective analyses were conducted of outpatients treated at an urticaria specialist center of a university hospital. Participants included 25 consecutive patients (aged 18-74 years; 18 women) with chronic spontaneous urticaria, chronic inducible urticaria, or both who showed complete response to omalizumab treatment, experienced relapse after discontinuation of treatment, and received retreatment with omalizumab.
INTERVENTIONS: Subcutaneous treatment with omalizumab (150-600 mg/mo).
MAIN OUTCOMES AND MEASURES: Response after retreatment was assessed by the urticaria activity score in patients with chronic spontaneous urticaria and by trigger threshold testing (in patients with cold urticaria or symptomatic dermographism) and/or a carefully determined history (in patients with cholinergic urticaria, solar urticaria, or pressure urticaria). Adverse events were documented.
RESULTS: All patients experienced complete response after retreatment. None of the patients reported relevant adverse events during omalizumab treatment and retreatment.
CONCLUSIONS AND RELEVANCE: Omalizumab retreatment is effective and safe in patients with chronic urticaria who have benefited from initial omalizumab treatment.
Предметные рубрики MeSH
AdolescentAdultAgedAmbulatory CareAnti-Allergic AgentsAntibodies, Anti-IdiotypicAntibodies, Monoclonal, HumanizedChronic DiseaseDose-Response Relationship, DrugDrug Administration ScheduleFemaleFollow-Up StudiesHospitals, UniversityHumansInjections, SubcutaneousMaleMiddle AgedOmalizumabPatient SafetyRecurrenceRetreatmentRisk AssessmentSeverity of Illness IndexTreatment OutcomeUrticariaYoung Adult